We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 309

Patent held to not be infringed based on the construction of the claims
  • Borden Ladner Gervais LLP
  • Canada
  • April 14 2016

Apotex sent a NOA to Shire alleging its patent was invalid and will not be infringed by Apotex. The issues were narrowed for the hearing, where


Motion for Interim Injunction Dismissed for Failing to Establish Irreparable Harm
  • Borden Ladner Gervais LLP
  • Canada
  • April 14 2016

TearLab brought a motion for an interim injunction, with the hearing for an interlocutory injunction being scheduled in late April or May. TearLab is


Witness' Evidence Given Less Weight because not Blinded to Patent or Issues; NOC Proceeding Dismissed
  • Borden Ladner Gervais LLP
  • Canada
  • April 14 2016

Apotex sent a NOA in respect of a single patent, alleging obviousness and lack of utility. The Court held that allegation was justified. In


Motion challenging the listing of a patent on the patent register filed before the 2015 amendments to the PM(NOC) Regulations is decided on the basis of the old regulations
  • Borden Ladner Gervais LLP
  • Canada
  • March 16 2016

Apotex has successfully challenged the listing of a patent on the Patent Register pursuant to Paragraph 4(2)(a) of the PM(NOC) Regulations. The


Supreme Court Leave to Appeal Granted
  • Borden Ladner Gervais LLP
  • Canada
  • March 16 2016

The Supreme Court has granted AstraZeneca leave to appeal in its application which asks the correct applicable standard for patent utility in Canada


Supreme Court Upcoming Leave to Appeal Decisions
  • Borden Ladner Gervais LLP
  • Canada
  • March 9 2016

The Supreme Court will announce the result of a leave application which asks the correct applicable standard for patent utility in Canada and whether


Compound patent held to be not soundly predicted for the level of promised utility found by the Court
  • Borden Ladner Gervais LLP
  • Canada
  • February 24 2016

The Federal Court has dismissed an application for prohibition concerning the drug ALIMTA. Although the parties joined issue on a significant number


Standard of Review of Palpable and Overriding Error Not Applied in Appeal from Rule 51 Appeal
  • Borden Ladner Gervais LLP
  • Canada
  • January 27 2016

This is an appeal from the Federal Court's (FC) decision (2015 FC 797), which upheld the Prothonotary's decision allowing the generic Respondent's


Court grants prohibition order; finds allegations of obviousness, lack of utility and insufficiency not justified
  • Borden Ladner Gervais LLP
  • Canada
  • January 20 2016

In a decision issued on November 18, 2015, the Federal Court allowed the proceeding, granting Leo Pharma a prohibition order in relation to its


Supreme Court to Issue Decision in Leave Application Re Claim for Unjust Enrichment in S. 8 Proceeding
  • Borden Ladner Gervais LLP
  • Canada
  • January 13 2016

The Supreme Court of Canada has announced that on Thursday, January 14, 2016 it will issue its decision in Apotex' application for leave to appeal